B+
Bull case
25%
Probability
Target price
$14.00
+45.4% vs current
ATRA
Atara BiotherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$8.00
-16.9% vs current
B-
Bear case
30%
Probability
Target price
$4.50
-53.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+34.8
Score
AI commentary
Headline flow is unusually busy for a low-coverage micro-cap, but it is mixed: March and April 2026 included lawsuit and listing-pressure headlines, while May 7, 2026 brought a clearly positive regulatory headline. Trusted market coverage described the May 7 move as a sharp rally of roughly 40% on the FDA resubmission-path update, consistent with a relief reaction rather than a de-risked fundamental rerating. Also, the queued post-earnings follow-up appears stale: in checked primary company sources, the latest confirmed financial release was March 16, 2026, and no separate Q1 2026 earnings release tied to May 6, 2026 was located as of May 9, 2026, which lowers confidence in any earnings-revision read-through.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15eventTab-cel resubmission framework after FDA Type A meetingHigh impact
On May 7, 2026, Atara said Pierre Fabre and Atara had a productive Type A meeting and that FDA agreed a single-arm study with an appropriate pre-specified historical control could support a future tab-cel marketing application; management said it expects a further regulatory update in Q3 2026 [#8-K-2026-05-07].
2026-10-27catalystNasdaq compliance windowHigh impact
A May 1, 2026 8-K said Nasdaq notified Atara it was below the $50 million minimum market value of listed securities requirement and gave the company until October 27, 2026 to regain compliance; failure to do so could push a market-transfer or delisting process [#8-K-2026-05-01].
2026-12-31catalystFinancing or strategic-transaction resolutionHigh impact
The March 16, 2026 10-K disclosed $8.5 million of year-end cash and said existing resources were not sufficient to fund planned operations for at least 12 months, raising substantial doubt about going concern, while the company continued to review strategic alternatives including merger, asset sale, licensing, or other transactions [#10-K-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology